3-(2-carboxyethyl)-4,5,6,7-tetrahydroindole | 245036-13-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(2-carboxyethyl)-4,5,6,7-tetrahydroindole
• 英文别名: 3-(4,5,6,7-tetrahydro-1H-indol-3-yl)-propionic acid；3-(4,5,6,7-tetrahydro-1H-indol-3-yl)propanoic acid
• CAS: 245036-13-9
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: NSPAIMACKXPNHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-carboxyethyl)-4,5,6,7-tetrahydroindole 在 盐酸 、 sodium hydroxide 、 三氯氧磷 作用下， 以 N-甲基乙酰胺 、 二氯甲烷 、 水 为溶剂， 以31%的产率得到3-(2-formyl-4,5,6,7-tetrahydro-1H-indol-3-yl)propionic acid
  参考文献：
  名称：

  Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis

  摘要：

  本发明涉及治疗与未受调控的血管生成和/或血管发生相关的疾病和紊乱的方法。更具体地，本发明涉及使用吲哚酮类化合物治疗疾病和紊乱的方法，例如类风湿关节炎、子宫内膜异位症、眼部新生血管生成、实体肿瘤生长和转移，以及伤口愈合过程中的过度瘢痕。

  公开号：

  US06846839B1
• 作为产物：
  描述：

  1-吗啉基-1-环己烯 在 盐酸 、 sodium hydroxide 、 sodium acetate 、 三乙胺 作用下， 以 二氯甲烷 、 溶剂黄146 为溶剂， 反应 3.83h， 生成 3-(2-carboxyethyl)-4,5,6,7-tetrahydroindole
  参考文献：
  名称：

  Identification of Substituted 3-[(4,5,6,7-Tetrahydro-1H-indol-2-yl)methylene]- 1,3-dihydroindol-2-ones as Growth Factor Receptor Inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ Tyrosine Kinases

  摘要：

  A series of new 3-substituted indolin-2-ones containing a tetrahydroindole moiety was developed as specific inhibitors of receptor tyrosine kinases associated with VEGF-R, FGF-R, and PDGF-R growth factor receptors. These compounds were evaluated for their inhibitory properties toward VEGF-R2 (Flk-1/KDR), FGF-R1, PDGF-R beta, p60(c-Src), and EGF-R tyrosine kinases and their ability to inhibit growth factor-dependent cell proliferation. Structure-activity relationships of this new pharmacophore have been determined at the level of kinase inhibition. Compounds containing a propionic acid moiety at the C-3' position of the tetrahydroindole ring represented the most potent indolin-2-ones to inactivate the VEGF, FGF, and PDGF receptor kinases. The inhibitory activities of 9d against VEGF-R2 (Flk-1), 9h against FGF-R1, and 9b against PDGF-R beta were 4, 80, and 4 nM, respectively. However, all of these compounds were inactive when tested against the EGF-R tyrosine kinase. Compounds 9a and 9b represented the most potent inhibitors of these classes to inhibit both biochemical kinase and growth factor-dependent cell proliferation for these three targets. In addition, compound 9a was cocrystallized with the catalytic domain of FGF-R1 providing evidence to explain the structure-activity relationship results. This study has provided evidence to support the potential of these new tyrosine kinase inhibitors for the treatment of angiogenesis and other growth factor-related diseases including human cancers.

  DOI：

  10.1021/jm9906116

文献信息

• Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
  申请人：SUGEN, INC.

  公开号：US20040067531A1

  公开（公告）日：2004-04-08

  The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds. The invention also relates to methods of modulating the function of protein tyrosine kinases using indolinone compounds and methods of treating diseases by modulating the function of protein tyrosine kinases and related signal transduction pathways.

  这项发明涉及某些吲哚酮化合物、它们的合成方法以及由这些吲哚酮化合物组成的组合式库。该发明还涉及使用吲哚酮化合物调节蛋白酪氨酸激酶功能的方法，以及通过调节蛋白酪氨酸激酶和相关信号转导途径的功能来治疗疾病的方法。
• 3-methylidenyl-2-indolinone modulators of protein kinase
  申请人：Sugen, Inc.

  公开号：US20040024010A1

  公开（公告）日：2004-02-05

  The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及新型的3-甲基亚烯基-2-吲哚酮化合物及其生理上可接受的盐和前药，这些化合物可调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面具有用途。
• 3-Methylidenyl-2-indolinone modulators of protein kinase
  申请人：Sugen, Inc.

  公开号：US06531502B1

  公开（公告）日：2003-03-11

  The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及新型的3-甲基亚乙烯基-2-吲哚酮化合物及其生理上可接受的盐和前药，其调节蛋白激酶活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面有用。
• HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE
  申请人：Sugen, Inc.

  公开号：EP1066257A2

  公开（公告）日：2001-01-10
• US6531502B1
  申请人：——

  公开号：US6531502B1

  公开（公告）日：2003-03-11